Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys145 or Lys146 from fPSA without internal cleavages at Lys145 or Lys146

Journal of Immunological Methods

Volumn 369, Issue 1-2, 2011, Pages 74-80

  Peltola, Mari T ^a   Niemelä, Pauliina ^a   Alanen, Kalle ^b   Nurmi, Martti ^b   Lilja, Hans ^c,d   Pettersson, Kim ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Free PSA isoform; Immunoassay; Internally cleaved PSA; Nicked PSA; Prostate cancer; Prostate specific antigen

Indexed keywords

HEPARIN; ISOPROTEIN; LYSINE; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

ACINAR CELL; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CALIBRATION; CANCER DIAGNOSIS; CANCER RISK; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; PROTEIN CLEAVAGE; PROTEIN PURIFICATION; REGRESSION ANALYSIS; RISK ASSESSMENT; SEMINAL PLASMA; SENSITIVITY AND SPECIFICITY;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOASSAY; MALE; PROSTATE-SPECIFIC ANTIGEN; SENSITIVITY AND SPECIFICITY;

EID: 79958838315     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2011.04.006     Document Type: Article

References (43)

1. Catalona W.J., Smith D.S., Ratliff T.L., Dodds K.M., Coplen D.E., Yuan J.J., Petros J.A., Andriole G.L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 1991, 324:1156.
2. Catalona W.J., Partin A.W., Slawin K.M., Brawer M.K., Flanigan R.C., Patel A., Richie J.P., deKernion J.B., Walsh P.C., Scardino P.T., Lange P.H., Subong E.N., Parson R.E., Gasior G.H., Loveland K.G., Southwick P.C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. Jama 1998, 279:1542.
3. Chen Z., Chen H., Stamey T.A. Prostate specific antigen in benign prostatic hyperplasia: purification and characterization. Journal Of Urology 1997, 157:2166.
4. Christensson A., Laurell C.B., Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem. 1990, 194:755.
5. Christensson A., Bjork T., Nilsson O., Dahlen U., Matikainen M.T., Cockett A.T., Abrahamsson P.A., Lilja H. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J. Urol. 1993, 150:100.
6. Crawford E.D., Grubb R., Black A., Andriole G.L., Chen M.H., Izmirlian G., Berg C.D., D'Amico A.V. Comorbidity and mortality results from a randomized prostate cancer screening trial. J. Clin. Oncol. 2011, 29:355.
7. Eriksson S., Vehniainen M., Jansen T., Meretoja V., Saviranta P., Pettersson K., Lovgren T. Dual-label time-resolved immunofluorometric assay of free and total prostate-specific antigen based on recombinant Fab fragments. Clin. Chem. 2000, 46:658.
8. Gupta A., Roobol M.J., Savage C.J., Peltola M., Pettersson K., Scardino P.T., Vickers A.J., Schroder F.H., Lilja H. A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br. J. Cancer 2010, 103:708.
9. Hugosson J., Carlsson S., Aus G., Bergdahl S., Khatami A., Lodding P., Pihl C.G., Stranne J., Holmberg E., Lilja H. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010, 11:725.
10. Jansen F.H., van Schaik R.H., Kurstjens J., Horninger W., Klocker H., Bektic J., Wildhagen M.F., Roobol M.J., Bangma C.H., Bartsch G. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur. Urol. 2010, 57:921.
11. Kort S.A., Martens F., Vanpoucke H., van Duijnhoven H.L., Blankenstein M.A. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin. Chem. 2006, 52:1568.
12. Lilja H., Christensson A., Dahlen U., Matikainen M.T., Nilsson O., Pettersson K., Lovgren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin. Chem. 1991, 37:1618.
13. Lilja H., Ulmert D., Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer 2008, 8:268.
14. Linton H.J., Marks L.S., Millar L.S., Knott C.L., Rittenhouse H.G., Mikolajczyk S.D. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin. Chem. 2003, 49:253.
15. Lovgren J., Rajakoski K., Karp M., Lundwall a., Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem. Biophys. Res. Commun. 1997, 238:549.
16. Mikolajczyk S.D., Millar L.S., Wang T.J., Rittenhouse H.G., Wolfert R.L., Marks L.S., Song W., Wheeler T.M., Slawin K.M. "BPSA", a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000, 55:41.
17. Mikolajczyk S.D., Catalona W.J., Evans C.L., Linton H.J., Millar L.S., Marker K.M., Katir D., Amirkhan A., Rittenhouse H.G. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin. Chem. 2004, 50:1017.
18. Mikolajczyk S.D., Song Y., Wong J.R., Matson R.S., Rittenhouse H.G. Are multiple markers the future of prostate cancer diagnostics?. Clin. Biochem. 2004, 37:519.
19. Nurmikko P., Vaisanen V., Piironen T., Lindgren S., Lilja H., Pettersson K. Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA. Clin. Chem. 2000, 46:1610.
20. Nurmikko P., Pettersson K., Piironen T., Hugosson J., Lilja H. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin. Chem. 2001, 47:1415.
21. Peltola, M., Niemelä, P., Väisänen, V., Viitanen, T., Alanen, K., Nurmi, M., Petterson, K., 2011. Intact and internally cleaved free prostate-specific antigen in prostate cancer patients with different pathological stages and grades. Urology 77, 1009.e1.
22. Peter J., Unverzagt C., Krogh T.N., Vorm O., Hoesel W. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res. 2001, 61:957.
23. Pettersson K.S., Soderholm J.R. Ultrasensitive two-site immunometric assay of human lutropin by time-resolved fluorometry. Clin. Chem. 1990, 36:1928.
24. Pettersson K., Piironen T., Seppala M., Liukkonen L., Christensson A., Matikainen M.T., Suonpaa M., Lovgren T., Lilja H. Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex. Clin. Chem. 1995, 41:1480.
25. Piironen T., Nurmi M., Irjala K., Heinonen O., Lilja H., Lovgren T., Pettersson K. Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing. Clin. Chem. 2001, 47:703.
26. Rafferty B., Rigsby P., Rose M., Stamey T., Gaines Das R. Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10). Clin. Chem. 2000, 46:1310.
27. Rajakoski K., Piironen T., Pettersson K., Lovgren J., Karp M. Epitope mapping of human prostate specific antigen and glandular kallikreins expressed in insect cells. Prostate Cancer Prostatic Dis. 1997, 1:16.
28. Schroder F.H., Hugosson J., Roobol M.J., Tammela T.L., Ciatto S., Nelen V., Kwiatkowski M., Lujan M., Lilja H., Zappa M., Denis L.J., Recker F., Berenguer A., Maattanen L., Bangma C.H., Aus G., Villers A., Rebillard X., van der Kwast T., Blijenberg B.G., Moss S.M., de Koning H.J., Auvinen A. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 2009, 360:1320.
29. Sobin LH, W.C. (1997) TNM Classification of Malignant Tumours. Wiley-Liss Inc., New York.
30. Stephan C., Klaas M., Muller C., Schnorr D., Loening S.A., Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin. Chem. 2006, 52:59.
31. Stephan C., Cammann H., Deger S., Schrader M., Meyer H.A., Miller K., Lein M., Jung K. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network. Urology 2009, 74:873.
32. Steuber T., Nurmikko P., Haese A., Pettersson K., Graefen M., Hammerer P., Huland H., Lilja H. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. J. Urol. 2002, 168:1917.
33. Steuber T., Niemela P., Haese A., Pettersson K., Erbersdobler A., Felix Chun K.H., Graefen M., Kattan M.W., Huland H., Lilja H. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. Prostate 2005, 63:13.
34. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., Minasian L.M., Ford L.G., Lippman S.M., Crawford E.D., Crowley J.J., Coltman C.A. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0ng per milliliter. N. Engl. J. Med. 2004, 350:2239.
35. Ulmert D., Becker C., Nilsson J.A., Piironen T., Bjork T., Hugosson J., Berglund G., Lilja H. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin. Chem. 2006, 52:235.
36. Vaisanen V., Lovgren J., Hellman J., Piironen T., Lilja H., Pettersson K. Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells. Prostate Cancer Prostatic Dis. 1999, 2:91.
37. Vaisanen V., Eriksson S., Ivaska K.K., Lilja H., Nurmi M., Pettersson K. Development of sensitive immunoassays for free and total human glandular kallikrein 2. Clin. Chem. 2004, 50:1607.
38. Vaisanen V., Peltola M.T., Lilja H., Nurmi M., Pettersson K. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments. Anal. Chem. 2006, 78:7809.
39. Vickers A.J., Cronin A.M., Aus G., Pihl C.G., Becker C., Pettersson K., Scardino P.T., Hugosson J., Lilja H. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med. 2008, 6:19.
40. Vickers A., Cronin A., Roobol M., Savage C., Peltola M., Pettersson K., Scardino P.T., Schroder F., Lilja H. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J. Clin. Oncol. 2010, 28:2493.
41. Vickers A.J., Cronin A.M., Bjork T., Manjer J., Nilsson P.M., Dahlin A., Bjartell A., Scardino P.T., Ulmert D., Lilja H. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. Bmj 2010, 341:c4521.
42. Zhang W.M., Leinonen J., Kalkkinen N., Dowell B., Stenman U.H. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin. Chem. 1995, 41:1567.
43. Zhang W.M., Finne P., Leinonen J., Vesalainen S., Nordling S., Rannikko S., Stenman U.H. Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. Clin. Chem. 1998, 44:2471.